Radiopharmaceuticals for imaging gliomas using positron emission tomography

1. Fadrus P, Šlampa P, Lakomý R et al. Komplexní terapie gliomů mozku. Onkologie 2015;9:214-217

2. Rohren EM, Turkington TG, Coleman RE. Clinical Applications of PET in Oncology. Radiology 2004;231:305-332

3. Wiebe LI. FDG Metabolism: Quaecumque Sunt Vera J Nucl Med 2001;42:1679-1681

4. Pirotte B, Goldman S, Massager N et al. Comparison of 18F-FDG and 11C-Methionine for PET-Guided Stereotactic Brain Biopsy of Gliomas. J Nucl Med 2004;45:1293-1298

5. Saha GB. Fundamentals of Nuclear Pharmacy – 6th edition. Springer Verlag, New York, 2010,409 p

6. Chen W. Clinical Applications of PET in Brain Tumors. J Nucl Med 2007;48:1468-1481

7. Fulham MJ, Brunetti A, Aloj L et al. Decreased cerebral glucose metabolism in patients with brain tumors: an effect of corticosteroids. J Neurosurg 1995;83:657-664

8. The EANM Technologist Comittee. Testanera G, van der Broek WJ (Editors). Principles and Practice of PET/CT - A Technologist‘s Guide, Part 2. Vienna, European Association of Nuclear Medicine, 2011,163 p

9. Smits A, Baumert BG. The Clinical Value of PET with Amino Acid Tracers for Gliomas WHO Grade II. Int J Mol Imaging 2011;2011:372509. doi:10.1155/2011/372509

10. Langen KJ, Jarosch M, Mühlensiepen H et al. Comparison of fluorotyrosines and methionine uptake in F98 rat gliomas. Nucl Med Biol 2003;30:501-508

11. Pöpperl G, Kreth FW, Herms J et al. Analysis of 18F-FET PET for Grading of Recurrent Gliomas: Is Evaluation of Uptake Kinetics Superior to Standard Methods? J Nucl Med 2006;47:393-403

12. Gempt J, Bette S, Ryang YM et al. 18F-fluoro-ethyl-tyrosine positron emission tomography for grading and estimation of prognosis in patients with intracranial gliomas. Eur J Radiol 2015;84:955-962

13. Narayanan T, Said S, Mukherjee J et al. A Comparative Study on the Uptake and Incorporation of Radiolabeled Methionine, Choline and Fluorodeoxyglucose in Human Astrocytoma. Mol Imaging Biol 2002;4:147-156

14. Langen KJ, Ziemons K, Kiwit JC et al. 3-[123I]Iodo-α-Methyltyrosine and [Methyl-11C]-L-Methionine Uptake in Cerebral Gliomas: A Comparative Study Using SPECT and PET. J Nucl Med 1997;38:517-522

15. Shishido H, Kawai N, Yamamoto Y et al. Diagnostic value of 11C-methionine (MET) and 18F-fluorothymidine (FLT) positron emission tomography in recurrent high-grade gliomas: Differentiation from treatment-induced tissue necrosis. J Nucl Med 2012;53(suppl.1):1988

16. Ribom D, Eriksson A, Hartman M et al. Positron emission tomography 11C-methionine and survival in patients with low-grade gliomas. Cancer 2001;92:1541-1549

17. Cicuendez M, Lorenzo-Bosquet C, Cuberas-Borrós G et al. Role of [11C] methionine positron emission tomography in the diagnosis and prediction of survival in brain tumours. Clin Neurol Neurosurg 2015;139:328-333

18. Beggs AD, Hain SF. Localization of parathyroid adenomas using 11C-methionine positron emission tomography. Nucl Med Commun 2005;26:133-136

19. Pauleit D, Stoffels G, Schaden W et al. PET with O-(2-18F-Fluoroethyl)-l-Tyrosine in Peripheral Tumors: First Clinical Results. J Nucl Med 2005;46:411-416

20. Nowosielski M, DiFranco MD, Putzer D et al. An Intra-Individual Comparison of MRI, [18F]-FET and [18F]-FLT PET in Patients with High-Grade Gliomas. PLOS ONE 2014;9:1-8

21. Langen KJ, Hamacher K, Weckesser M et al. O-(2-[18F]fluoroethyl)-l-tyrosine: uptake mechanisms and clinical applications. Nucl Med Biol 2006;33:287-294

22. Pauleit D, Stoffels G, Bachofner A et al. Comparison of 18F-FET and 18F-FDG PET in brain tumors. Nucl Med Biol 2009;36:779-787

23. Weber W, Wester H, Grosu A et al. O-(2-[18F]fluoroethyl)-L-tyrosine and L-[methyl-11C]methionine uptake in brain tumours: initial results of a comparative study. Eur J Nucl Med 2000;27:542-549

24. Pöpperl G, Götz C, Rachinger W et al. Value of O-(2-[18F]fluoroethyl)-l-tyrosine PET for the diagnosis of recurrent glioma. Eur J Nucl Med Mol Imaging 2004;31:1464-1470

25. Jager PL, Vaalburg W, Pruim J et al. Radiolabeled Amino Acids: Basic Aspects and Clinical Applications in Oncology. J Nucl Med 2001;42:432-445

26. Chen W, Silverman DH, Delaloye S et al. 18F-FDOPA PET Imaging of Brain Tumors: Comparison Study with 18F-FDG PET and Evaluation of Diagnostic Accuracy. J Nucl Med 2006;47:904-911

27. Chevalme YM, Montravers F, Vuillez JP et al. FDOPA-(18F): a PET radiopharmaceutical recently registered for diagnostic use in countries of the European Union. Braz Arch Biol Technol 2007;50:77-90

28. Becherer A, Karanikas G, Szabó M et al. Brain tumour imaging with PET: a comparison between [18F]fluorodopa and [11C]methionine. Eur J Nucl Med Mol Imaging 2003;30:1561-1567

29. Wells J, Mankoff D, Muzi M et al. Kinetic analysis of 2-[11C]thymidine PET imaging studies of malignant brain tumors: compartmental model investigation and mathematical analysis. Mol Imaging 2002;1:151-159

30. Muzi M, Spence AM, O‘Sullivan F et al. Kinetic Analysis of 3′-Deoxy-3′-18F-Fluorothymidine in Patients with Gliomas. J Nucl Med 2006;47:1612-1621

31. Grierson JR, Schwartz JL, Muzi M et al. Metabolism of 3‘-deoxy-3‘-[F-18]fluorothymidine in proliferating A549 cells: Validations for positron emission tomography. Nucl Med Biol 2004;31:829-837

32. Laymon CM, Oborski MJ, Lee VK et al. Combined imaging biomarkers for therapy evaluation in glioblastoma multiforme: correlating sodium MRI and F-18 FLT PET on a voxel-wise basis. Magn Reson Imaging 2012;30:1268-1278

33. Jeong SY, Lim SM. Comparison of 3‘-deoxy-3‘-[18F]fluorothymidine PET and O-(2-[18F]fluoroethyl)-L-tyrosine PET in patients with newly diagnosed glioma. Nucl Med Biol 2012;39:977-981

34. Giovannini E, Lazzeri P, Milano A et al. Clinical Applications of Choline PET/CT in Brain Tumors. Curr Pharm Des 2015;21:121-127

35. Kato T, Shinoda J, Nakayama N et al. Metabolic Assessment of Gliomas Using 11C-Methionine, [18F] Fluorodeoxyglucose, and 11C-Choline Positron-Emission Tomography. Am J Neuroradiol 2008;29:1176-1182

36. Tian M, Zhang H, Oriuchi N et al. Comparison of 11C-choline PET and FDG PET for the differential diagnosis of malignant tumors. Eur J Nucl Med Mol Imaging 2004;31:1064-1072

37. Huang Z, Zuo C, Guan Y et al. Misdiagnoses of 11C-choline combined with 18F-FDG PET imaging in brain tumours. Nucl Med Commun 2008;29:354-358

38. Tan H, Chen L, Guan Y et al. Comparison of MRI, F-18 FDG, and 11C-Choline PET/CT for Their Potentials in Differentiating Brain Tumor Recurrence From Brain Tumor Necrosis Following Radiotherapy. Clin Nucl Med 2011;36:978-981

39. Kwee SA, DeGrado TR, Talbot JN et al. Cancer Imaging With Fluorine-18-Labeled Choline Derivatives. Semin Nucl Med 2007;37:420-428

40. Hara T, Kondo T, Hara T et al. Use of 18F-choline and 11C-choline as contrast agents in positron emission tomography imaging-guided stereotactic biopsy sampling of gliomas. J Neurosurg 2003;99:474-9

41. Liu RS, Chang CP, Chu LS et al. PET imaging of brain astrocytoma with 1-11C-acetate. Eur J Nucl Med Mol Imaging 2006;33:420-427

42. Yamamoto Y, Nishiyama Y, Kimura N et al. 1C-Acetate PET in the Evaluation of Brain Glioma: Comparison with 11C-Methionine and 18F-FDG-PET. Mol Imaging Biol 2008;10:281

43. Krohn KA, Link JM, Mason RP. Molecular Imaging of Hypoxia. J Nucl Med 2008;49(suppl 2):129S-148S

44. Bruehlmeier M, Roelcke U, Schubiger PA et al. Assessment of Hypoxia and Perfusion in Human Brain Tumors Using PET with 18F-Fluoromisonidazole and 15O-H2O. J Nucl Med 2004;45:1851-1859

45. Mönnich D, Troost EGC, Kaanders JHAM. Modelling and simulation of [ 18 F]fluoromisonidazole dynamics based on histology-derived microvessel maps. Phys Med Biol 2011;56:2045

46. Rajendran JG, Wilson DC, Conrad EU et al. [18F]FMISO and [18F]FDG PET imaging in soft tissue sarcomas: correlation of hypoxia, metabolism and VEGF expression. Eur J Nucl Med Mol Imaging 2003;30:695-704

47. Eschmann SM, Paulsen F, Reimold M et al. Prognostic Impact of Hypoxia Imaging with 18F-Misonidazole PET in Non-Small Cell Lung Cancer and Head and Neck Cancer Before Radiotherapy. J Nucl Med 2005;46:253-260

48. Postema EJ, McEwan AJB, Riauka TA et al. Initial results of hypoxia imaging using 1-alpha-D-(5-deoxy-5-[18F]-fluoroarabinofuranosyl)-2-nitroimidazole (18F-FAZA). Eur J Nucl Med Mol Imaging 2009;36:1565-1573

49. Sorger D, Patt M, Kumar P et al. [18F]Fluoroazomycinarabinofuranoside (18FAZA) and [18F]Fluoromisonidazole (18FMISO): a comparative study of their selective uptake in hypoxic cells and PET imaging in experimental rat tumors. Nucl Med Biol 2003;30:317-326

50. Koch CJ, Scheuermann JS, Divgi C et al. Biodistribution and dosimetry of 18F-EF5 in cancer patients with preliminary comparison of 18F-EF5 uptake versus EF5 binding in human glioblastoma. Eur J Nucl Med Mol Imaging 2010;37:2048-2059

51. Yang DJ, Wallace S, Cherif A et al. Development of F-18-labeled fluoroerythronitroimidazole as a PET agent for imaging tumor hypoxia. Radiology 1995;194:795-800

52. Zanzonico P, O‘Donoghue J, Chapman JD et al. Iodine-124-labeled iodo-azomycin-galactoside imaging of tumor hypoxia in mice with serial microPET scanning. Eur J Nucl Med Mol Imaging 2004;31:117-128

53. Lapi SE, Lewis JS, Dehdashti F. Evaluation of Hypoxia With Copper-Labeled Diacetyl-bis(N-Methylthiosemicarbazone). Semin Nucl Med 2015;45:177-185

54. Zhang T, Das SK, Fels DR et al. PET with 62Cu-ATSM and 62Cu-PTSM Is a Useful Imaging Tool for Hypoxia and Perfusion in Pulmonary Lesions. Am J Roentgenol 2013;201:698-706

55. Sharma P, Mukherjee A, Bal C et al. Somatostatin Receptor–Based PET/CT of Intracranial Tumors: A Potential Area of Application for 68Ga-DOTA Peptides? Am J Roentgenol 2013;201:1340-1347

56. Heute D, Kostron H, von Guggenberg E et al. Response of Recurrent High-Grade Glioma to Treatment with 90Y-DOTATOC. J Nucl Med 2010;51:397-400

57. Sharma P, Dhull VS, Bal C et al. Von Hippel-Lindau Syndrome: Demonstration of Entire Disease Spectrum with 68Ga-DOTANOC PET-CT. Korean J Radiol 2014;15:169-172

58. Passah A, Tripathi M, Kumar R et al. Brain Metastasis in Carcinoma Breast Demonstrated on 68Ga NOTA-Bisphosphonate PET/CT. Clin Nucl Med 2014;39:653-654

59. Wang Z, Zhang M, Wang L et al. Study of 68Ga-NOTA-NFB: Radiation Dosimetry in Healthy Volunteers and First Application in Glioma Patients. J Nucl Med 2015;56(suppl 3):11

60. Chen K, Cai W, Li ZB et al. Quantitative PET Imaging of VEGF Receptor Expression. Mol Imaging Biol 2009;11:15-22

61. Schnell O, Krebs B, Carlsen J et al. Imaging of integrin αvβ3 expression in patients with malignant glioma by [18F] Galacto-RGD positron emission tomography. Neuro-oncol 2009;11:861-870

62. Li D, Zhao X, Zhang L et al. 68Ga-PRGD2 PET/CT in the Evaluation of Glioma: A Prospective Study. Mol Pharm 2014;11:3923-3929

63. Iagaru A, Mosci C, Mittra E et al. Glioblastoma Multiforme Recurrence: An Exploratory Study of 18F FPPRGD2 PET/CT. Radiology 2015;277:497-506

64. Yu C, Pan D, Mi B et al. 18F-Alfatide II PET/CT in healthy human volunteers and patients with brain metastases. Eur J Nucl Med Mol Imaging 2015;42:2021-2028